These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

189 related items for PubMed ID: 12111113

  • 1. Urinary and fecal excretion of topotecan in patients with malignant solid tumours.
    Herben VM, Schoemaker nE, Rosing H, van Zomeren DM, ten Bokkel Huinink WW, Dubbelman R, Hearn S, Schellens JH, Beijnen JH.
    Cancer Chemother Pharmacol; 2002 Jul; 50(1):59-64. PubMed ID: 12111113
    [Abstract] [Full Text] [Related]

  • 2. Oral topotecan: bioavailablity and effect of food co-administration.
    Herben VM, Rosing H, ten Bokkel Huinink WW, van Zomeren DM, Batchelor D, Doyle E, Beusenberg FD, Beijnen JH, Schellens JH.
    Br J Cancer; 1999 Jul; 80(9):1380-6. PubMed ID: 10424739
    [Abstract] [Full Text] [Related]

  • 3. A comparison of clinical pharmacodynamics of different administration schedules of oral topotecan (Hycamtin).
    Gerrits CJ, Schellens JH, Burris H, Eckardt JR, Planting AS, van der Burg ME, Rodriguez GI, Loos WJ, van Beurden V, Hudson I, Von Hoff DD, Verweij J.
    Clin Cancer Res; 1999 Jan; 5(1):69-75. PubMed ID: 9918204
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Pretreatment with ranitidine does not reduce the bioavailability of orally administered topotecan.
    Akhtar S, Beckman RA, Mould DR, Doyle E, Fields SZ, Wright J.
    Cancer Chemother Pharmacol; 2000 Jan; 46(3):204-10. PubMed ID: 11021737
    [Abstract] [Full Text] [Related]

  • 9. A phase I study of sequential administration of escalating doses of intravenous paclitaxel, oral topotecan, and fixed-dose oral etoposide in patients with solid tumors.
    Rocha Lima CM, Catapano CV, Pacheco D, Sherman CA, Oakhill G, Mushtaq C, Freeman KD, Green MR.
    Cancer; 2004 Jun 15; 100(12):2671-9. PubMed ID: 15197811
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Elimination pathways of [14C]losoxantrone in four cancer patients.
    Joshi AS, Pieniaszek HJ, Vokes EE, Vogelzang NJ, Davidson AF, Richards LE, Chai MF, Finizio M, Ratain MJ.
    Drug Metab Dispos; 2001 Feb 15; 29(2):96-9. PubMed ID: 11159796
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
    Klein CE, Kastrissios H, Miller AA, Hollis D, Yu D, Rosner GL, Grinblatt DL, Larson RA, Ratain MJ.
    Cancer Chemother Pharmacol; 2006 Jan 15; 57(2):199-206. PubMed ID: 16158312
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics of aminomethylpropanol in rats following oral and a novel dermal study design.
    Saghir SA, Clark AJ, McClymont EL, Staley JL.
    Food Chem Toxicol; 2008 Feb 15; 46(2):678-87. PubMed ID: 17961896
    [Abstract] [Full Text] [Related]

  • 14. Phase I study of combined pegylated liposomal doxorubicin with protracted daily topotecan for ovarian cancer.
    Mirchandani D, Hochster H, Hamilton A, Liebes L, Yee H, Curtin JP, Lee S, Sorich J, Dellenbaugh C, Muggia FM.
    Clin Cancer Res; 2005 Aug 15; 11(16):5912-9. PubMed ID: 16115933
    [Abstract] [Full Text] [Related]

  • 15. Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
    Supko JG, Eder JP, Ryan DP, Seiden MV, Lynch TJ, Amrein PC, Kufe DW, Clark JW.
    Clin Cancer Res; 2003 Nov 01; 9(14):5178-86. PubMed ID: 14613997
    [Abstract] [Full Text] [Related]

  • 16. Interpatient variability in bioavailability of the intravenous formulation of topotecan given orally to children with recurrent solid tumors.
    Zamboni WC, Bowman LC, Tan M, Santana VM, Houghton PJ, Meyer WH, Pratt CB, Heideman RL, Gajjar AJ, Pappo AS, Stewart CF.
    Cancer Chemother Pharmacol; 1999 Nov 01; 43(6):454-60. PubMed ID: 10321504
    [Abstract] [Full Text] [Related]

  • 17. Phase I study of oral topotecan in hematological malignancies.
    Beran M, O'Brien S, Thomas DA, Tran HT, Cortes-Franco JE, Giles F, Estey E, Kantarjian HM.
    Clin Cancer Res; 2003 Sep 15; 9(11):4084-91. PubMed ID: 14519630
    [Abstract] [Full Text] [Related]

  • 18. Topotecan lacks third space sequestration.
    Gelderblom H, Loos WJ, Verweij J, de Jonge MJ, Sparreboom A.
    Clin Cancer Res; 2000 Apr 15; 6(4):1288-92. PubMed ID: 10778953
    [Abstract] [Full Text] [Related]

  • 19. Pharmacokinetics, metabolism, and routes of excretion of intravenous irofulven in patients with advanced solid tumors.
    Paci A, Rezai K, Deroussent A, De Valeriola D, Re M, Weill S, Cvitkovic E, Kahatt C, Shah A, Waters S, Weems G, Vassal G, Lokiec F.
    Drug Metab Dispos; 2006 Nov 15; 34(11):1918-26. PubMed ID: 16896064
    [Abstract] [Full Text] [Related]

  • 20. Population pharmacokinetic and adverse event analysis of topotecan in patients with solid tumors.
    Mould DR, Holford NH, Schellens JH, Beijnen JH, Hutson PR, Rosing H, ten Bokkel Huinink WW, Rowinsky EK, Schiller JH, Russo M, Ross G.
    Clin Pharmacol Ther; 2002 May 15; 71(5):334-48. PubMed ID: 12011819
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.